December 2, 2021

Earn Money

Business Life

Here’s Why We’re Not Too Worried About ZIOPHARM Oncology’s (NASDAQ:ZIOP) Cash Burn Situation

Even when a business is losing money, it’s possible for shareholders to make money if they buy a good business at the right price. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you’d have done very well indeed. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed.

Given this risk, we thought we’d take a look at whether ZIOPHARM Oncology (NASDAQ:ZIOP) shareholders should be worried about its cash burn. In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth. The first step is to compare its cash burn with its cash reserves, to give us its ‘cash runway’.

Check out our latest analysis for ZIOPHARM Oncology

When Might ZIOPHARM Oncology Run Out Of Money?

A cash runway is defined as the length of time it would take a company to run out of money if it kept spending at its current rate of cash burn. In March 2020, ZIOPHARM Oncology had US$171m in cash, and was debt-free. Looking at the last year, the company burnt through US$41m. That means it had a cash runway of about 4.1 years as of March 2020. A runway of this length affords the company the time and space it needs to develop the business. Depicted below, you can see how its cash holdings have changed over time.

NasdaqGS:ZIOP Historical Debt May 11th 2020

How Is ZIOPHARM Oncology’s Cash Burn Changing Over Time?

Because ZIOPHARM Oncology isn’t currently generating revenue, we consider it an early-stage business. So while we can’t look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. Cash burn was pretty flat over the last year, which suggests that management are holding spending steady while the business advances its strategy. While the past is always worth studying, it is the future that matters most of all. So you might want to take a peek at how much the company is expected to grow in the next few years.

Can ZIOPHARM Oncology Raise More Cash Easily?

While its cash burn is only increasing slightly, ZIOPHARM Oncology shareholders should still consider the potential need for further cash, down the track. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Many companies end up issuing new shares to fund future growth. By comparing a company’s annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate).

Since it has a market capitalisation of US$581m, ZIOPHARM Oncology’s US$41m in cash burn equates to about 7.1% of its market value. That’s a low proportion, so we figure the company would be able to raise more cash to fund growth, with a little dilution, or even to simply borrow some money.

So, Should We Worry About ZIOPHARM Oncology’s Cash Burn?

As you can probably tell by now, we’re not too worried about ZIOPHARM Oncology’s cash burn. For example, we think its cash runway suggests that the company is on a good path. Although its increasing cash burn does give us reason for pause, the other metrics we discussed in this article form a positive picture overall. Looking at all the measures in this article, together, we’re not worried about its rate of cash burn; the company seems well on top of its medium-term spending needs. Separately, we looked at different risks affecting the company and spotted 4 warning signs for ZIOPHARM Oncology (of which 1 can’t be ignored!) you should know about.

Of course ZIOPHARM Oncology may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

If you spot an error that warrants correction, please contact the editor at [email protected] This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Source Article